The goal of this activity is for learners to be better able to analyze the results of a recent phase 2, open-label multipart, multicenter study replacing vinblastine with nivolumab (brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine) compared with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine [A+AVD]).
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1002150
- Start Date: 2025-01-16 06:00:00
- End Date: 2025-01-16 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Journal-based CE
- CME Finder Type: Other
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
- Specialty: Hematology, Medical Oncology
Subscribe
Login
0 Comments
Oldest